This article is more than 5 years old. Information may no longer be current.
Beta-blockers may prevent complications from breast cancer therapy
Click Here to Manage Email Alerts
AHA Scientific Sessions 2011
ORLANDO, Fla. — Beta-blockers appear to help prevent CV-related complications associated with trastuzumab, according to results presented at the American Heart Association Scientific Sessions 2011.
Researchers studied data on 197 patients with breast cancer and no history of prior HF who were taking trastuzumab (Herceptin, Genentech). Thirty patients were assigned beta-blockers for high BP and other heart conditions before starting trastuzumab.
During 12 months, 14 patients developed a new diagnosis of HF and 72 developed a new diagnosis of left ventricular dysfunction. Fewer patients in the beta-blocker group had evidence of LV dysfunction than in the group that did not take beta-blockers, the researchers said. No patients in the beta-blocker group had HF during the study.
Although the researchers found a positive effect of beta-blockers, the same was not observed with ACE inhibitors, anthracycline or other types of chemotherapy before treatment with trastuzumab. However, current smokers were at significantly greater risk for LV dysfunction.
For more information:
- Cook TB. Abstract #13988. Presented at: American Heart Association Scientific Sessions 2011; Nov. 12-16, 2011; Orlando, Fla.
Disclosure: The researchers report no relevant financial disclosures.
 |
Follow CardiologyToday.com on Twitter. |